Search company, investor...


Founded Year



Series C - II | Alive

Total Raised


Last Raised

$1.97M | 4 yrs ago

About ValenTx

ValenTx is developing a new therapy to treat patients with obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. The company's technology mimics the therapeutic mechanisms of a Roux-en-Y gastric bypass, and does this with a non-surgical, endoluminal bypass device.

Headquarters Location

6901 East Fish Lake road Suite 118

Osseo, Minnesota, 55369,

United States


Missing: ValenTx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ValenTx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ValenTx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ValenTx is included in 4 Expert Collections, including Medical Devices.


Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,899 items


Health IT

7,901 items


Digital Health

310 items

ValenTx Patents

ValenTx has filed 1 patent.

The 3 most popular patent topics include:

  • Digestive system surgery
  • Bariatrics
  • Digestive system
patents chart

Application Date

Grant Date


Related Topics




Digestive system surgery, Bariatrics, Digestive system procedures, Obesity, Digestive system imaging


Application Date


Grant Date



Related Topics

Digestive system surgery, Bariatrics, Digestive system procedures, Obesity, Digestive system imaging



Latest ValenTx News

ValenTx raises $10.3 million for implantable gastric bypass device

Aug 17, 2018

Startup ValenTx has attracted nearly $10.3 million from 32 investors, according to a filing with the Securities & Exchange Commission. The Maple Grove, Minn. company is developing a removable gastric bypass device as an alternative to Roux-en-Y gastric bypass surgery. It raised $10,271,050 in the round begun July 18, 2018. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure, according to the company’s website. This procedure does not require gastric stapling or permanent changes to the patient’s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment toward the individual patient’s needs. ValenTx’s goal is to treat obesity and obesity-related metabolic disorders, such as type 2 diabetes and hypertension. The company’s board includes med tech veterans Paul LaViolette, formerly of Boston Scientific and now a Boston venture capitalist; and former Medtronic executive vice president Bob Griffin. ValenTx has conducted a series of clinical studies of the therapy, which has not received FDA approval. Studies are ongoing, according to the company, which did not reveal how it will use the money in its latest fundraising round.

ValenTx Frequently Asked Questions (FAQ)

  • When was ValenTx founded?

    ValenTx was founded in 2002.

  • Where is ValenTx's headquarters?

    ValenTx's headquarters is located at 6901 East Fish Lake road, Osseo.

  • What is ValenTx's latest funding round?

    ValenTx's latest funding round is Series C - II.

  • How much did ValenTx raise?

    ValenTx raised a total of $49.31M.

  • Who are the investors of ValenTx?

    Investors of ValenTx include SV Health Investors, TGap Ventures, Sapient Capital, EDF Ventures, Kaiser Permanente Ventures and 4 more.

  • Who are ValenTx's competitors?

    Competitors of ValenTx include Ivenix, Epitomee Medical, EndoGastric Solutions, ReShape Medical, SonarMed and 11 more.

Compare ValenTx to Competitors


Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.


EndoVx is developing a medical device system for non-invasively treating obesity. The procedure is quick and done on an out-patient basis.

EndoMetabolic Solutions

EndoMetabolic Solutions is developing a medical device for the surgical treatment of obesity.

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Power Medical Interventions

Power Medical Interventions (PMI) is a medical device company headquartered in Langhorne, Pennsylvania. Founded in 2000, PMI was formed for the purpose of designing, developing, and marketing new computerized and reusable devices and methods for delivering staples during surgery. This forms the basis of their SurgASSIST System which is a computer-mediated transection and anastomosis device.

Leptos BioMedical

Leptos Biomedical is developing an impressive new electrical stimulation device treating obesity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.